알림·소식
알림·소식
[2019 Pasteur Colloquium] Neil Carragher 교수, 영국 에딘버러대학교
2019-10-08
____________________________________________
[한국파스퇴르연구소] 파스퇴르 콜로퀴엄
일시 : 2019년 10월 11일 (금), 오전 11시
장소 : 모노드 회의실 (1층), 한국파스퇴르연구소
______________________________________________________________________________________________________
.png)
연자
Neil Carragher 교수
영국 에딘버러대학교 신약개발 교수
강연주제
Advances in Phenotypic Screening: Accelerating the Discovery of New Chemical Entities and Drug Combinations towards in vivo proof-of-concept
초록
Recent advances in high-content imaging, CRISPR/Cas-based genome editing, induced pluripotent stem cell technologies and high throughput genomic and proteomic capabilities are converging to stimulate the new discipline of Phenomics Drug Discovery. I will describe how Phenomics Drug Discovery incorporates state-of-the-art imaging, genomics, proteomics and informatics tools to provide important functional context and foundations for emerging Artificial Intelligence (A.I.) solutions which support the identification of novel drug mechanisms-of-action, drug combinations, biomarkers and novel chemical design across disease areas. As specific exemplar studies I will present our recent examples of the application of machine learning and deep learning approaches for classification of drug mechanism of action across genetically distinct cancer cell lines representing different clinical subtypes. I also highlight how our Phenomics Drug Discovery platform has enabled the rapid discovery of a novel orally-available kinase inhibitor and novel drug combinations which display potent anti-tumour activity across 2D, 3D and in vivo models.
___________________________________________
Recent advances in high-content imaging, CRISPR/Cas-based genome editing, induced pluripotent stem cell technologies and high throughput genomic and proteomic capabilities are converging to stimulate the new discipline of Phenomics Drug Discovery. I will describe how Phenomics Drug Discovery incorporates state-of-the-art imaging, genomics, proteomics and informatics tools to provide important functional context and foundations for emerging Artificial Intelligence (A.I.) solutions which support the identification of novel drug mechanisms-of-action, drug combinations, biomarkers and novel chemical design across disease areas. As specific exemplar studies I will present our recent examples of the application of machine learning and deep learning approaches for classification of drug mechanism of action across genetically distinct cancer cell lines representing different clinical subtypes. I also highlight how our Phenomics Drug Discovery platform has enabled the rapid discovery of a novel orally-available kinase inhibitor and novel drug combinations which display potent anti-tumour activity across 2D, 3D and in vivo models.
___________________________________________
*파스퇴르 콜로퀴엄 관련 문의사항은 sukyon.yang@ip-korea.org 로 이메일 송부 부탁드립니다. 연구소 관련 추가 내용은 홈페이지 (www.ip-korea.org) 를 통해 확인하실 수 있습니다.
** 한국파스퇴르연구소 약도: http://www.ip-korea.org/about_us/location.php